Share Prices & Company Research

Market News

01 Apr 2021 | 16:05

Diaceutics wins data deal with unnamed pharma firm

(Sharecast News) - Diaceutics has secured a data licensing agreement with an unnamed global pharmaceutical company to provide Covid-19 testing data insights in the US, it announced on Thursday, enabled by its proprietary diagnostic network 'DXRX'. The AIM-traded company said that with around 400 treatments for the coronavirus now in development, the contract win- which came as a result of insights made available by its recent algorithmic development of a Covid-19 diagnostic disease pathway (DDP) - showed the group was in a position to address the "imminent opportunity" presented by the Covid-19 treatment market.

It said the details of the contract, including the identity of the pharmaceutical company and the value, were confidential, and no further information could be disclosed.

The board did say that the contract value did not change management expectations of performance for the current financial year.

"We are delighted to be able to facilitate access to this valuable Covid-tested patient cohort," said chief executive officer Peter Keeling.

"This first Covid-19 data-licensing agreement for the company provides testing data insights and analytics to pharmaceutical companies actively developing treatments for the disease.

"With hundreds of Covid-19 treatments now in development to address a pandemic at global scale, it is critically important that pharmaceutical companies lean in towards digital testing solutions such as those enabled by DXRX, to ensure that they have the data insights, and testing infrastructure required to get patients tested and treated."

At 1503 BST, shares in Diaceutics were up 1.57% at 103.6p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.